here are the details concerning the stem cell trial at cleve clinics mellon center;
Sarah Planchon Pope, PhD, CCRP planchs@ccf.org
Mellen Center Currently Enrolling Treatment Trials
Study Name:
A Phase I study to assess the feasibility, safety, and tolerability of
autologous mesenchymal stem cell transplantation in patients with
relapsing forms of multiple sclerosis
autologous mesenchymal stem cell transplantation in patients with
relapsing forms of multiple sclerosis
Primary Investigator: Jeffrey Cohen, M.D.
Purpose: The main purpose of this study is to evaluate to feasibility, safety,
and tolerability of autologous mesenchymal stem cell
transplantation in multiple sclerosis
Entry requirements: All participants must be between 18 and 55, have a relapsing form
of MS, have moderate disability, be able to walk, have
involvement of the visual system and documented disease activity
within the last 2 years
Duration: Subjects will participate for approximately 8 months.
Study Assessments: The study is open label, all participants will receive the same
treatment Participants will have frequent study visits
All participants will have bone marrow taken from their hip.
Mesenchymal stem cells will be isolated from the bone marrow,
which will be grown in culture so that there are an increased
number of cells. The cells will be infused into the original
participants arm by IV. Intensive safety monitoring will occur in
the days and weeks following infusion.
EDSS, brain MRI scan, the 9Hole Peg Test, Timed 25-Foot Walk,
optical coherence tomography, visual evoked potential, EKG, chest
X-ray, physical and neurological examinations, vital signs,
laboratory, adverse events, medication monitoring will occur for
all participants.
For more information, please contact:
Cynthia Schwanger, RN, at
Purpose: The main purpose of this study is to evaluate to feasibility, safety,
and tolerability of autologous mesenchymal stem cell
transplantation in multiple sclerosis
Entry requirements: All participants must be between 18 and 55, have a relapsing form
of MS, have moderate disability, be able to walk, have
involvement of the visual system and documented disease activity
within the last 2 years
Duration: Subjects will participate for approximately 8 months.
Study Assessments: The study is open label, all participants will receive the same
treatment Participants will have frequent study visits
All participants will have bone marrow taken from their hip.
Mesenchymal stem cells will be isolated from the bone marrow,
which will be grown in culture so that there are an increased
number of cells. The cells will be infused into the original
participants arm by IV. Intensive safety monitoring will occur in
the days and weeks following infusion.
EDSS, brain MRI scan, the 9Hole Peg Test, Timed 25-Foot Walk,
optical coherence tomography, visual evoked potential, EKG, chest
X-ray, physical and neurological examinations, vital signs,
laboratory, adverse events, medication monitoring will occur for
all participants.
For more information, please contact:
Cynthia Schwanger, RN, at
schwanc@ccf.org or
Sarah Planchon Pope, PhD, CCRP planchs@ccf.org
Comment